C2 and cancer: Intriguingly, tumours characterized by higher myeloid and endothelial C2 signature scores exhibited worse overall survival across multiple cancer types, including lung cancer (LC), PAAD, and STAD, as well as in the pan-cancer model (Fig. 7c–f).